Abstract:Background: Diabetes is a risk factor for heart failure and promotes cardiac dysfunction. Diabetic tissues are associated with nicotinamide adenine dinucleotide (NAD+) redox imbalance; however, the hypothesis that NAD+ redox imbalance causes diabetic cardiomyopathy has not been tested. This investigation used mouse models with altered NAD+ redox balance to test this hypothesis. Methods: Diabetic stress was induced in mice by streptozotocin. Cardiac function was measured by echocardiography. Heart and plasma samples were collected for biochemical, histological, and molecular analyses. Two mouse models with altered NAD+ redox states (1, Ndufs4 [NADH:ubiquinone oxidoreductase subunit S4] knockout, cKO, and 2, NAMPT [nicotinamide phosphoribosyltranferase] transgenic mice, NMAPT) were used. Results: Diabetic stress caused cardiac dysfunction and lowered NAD+/NADH ratio (oxidized/reduced ratio of nicotinamide adenine dinucleotide) in wild-type mice. Mice with lowered cardiac NAD+/NADH ratio without baseline dysfunction, cKO mice, were challenged with chronic diabetic stress. NAD+ redox imbalance in cKO hearts exacerbated systolic (fractional shortening: 27.6% versus 36.9% at 4 weeks, male cohort P<0.05), and diastolic dysfunction (early-to-late ratio of peak diastolic velocity: 0.99 versus 1.20, P<0.05) of diabetic mice in both sexes. Collagen levels and transcripts of fibrosis and extracellular matrix-dependent pathways did not show changes in diabetic cKO hearts, suggesting that the exacerbated cardiac dysfunction was due to cardiomyocyte dysfunction. NAD+ redox imbalance promoted superoxide dismutase 2 acetylation, protein oxidation, troponin I S150 phosphorylation, and impaired energetics in diabetic cKO hearts. Importantly, elevation of cardiac NAD+ levels by NAMPT normalized NAD+ redox balance, alleviated cardiac dysfunction (fractional shortening: 40.2% versus 24.8% in cKO:NAMPT versus cKO, P<0.05; early-to-late ratio of peak diastolic velocity: 1.32 versus 1.04, P<0.05), and reversed pathogenic mechanisms in diabetic mice. Conclusions: Our results show that NAD+ redox imbalance to regulate acetylation and phosphorylation is a critical mediator of the progression of diabetic cardiomyopathy and suggest the therapeutic potential for diabetic cardiomyopathy by harnessing NAD+ metabolism.

Enhanced Catecholamine Flux and Impaired Carbonyl Metabolism Disrupt Cardiac Mitochondrial Oxidative Phosphorylation in Diabetes Patients

A Novel Protective Mechanism for Mitochondrial Aldehyde Dehydrogenase (aldh2) in Type I Diabetes-Induced Cardiac Dysfunction: Role of Ampk-Regulated Autophagy

Cardiac Monoamine Oxidase-a Inhibition Protects Against Catecholamine-Induced Ventricular Arrhythmias Via Enhanced Diastolic Calcium Control.

ACMSD Mediated De Novo NAD+ Biosynthetic Impairment in Cardiac Endothelial Cells As a Potential Therapeutic Target for Diabetic Cardiomyopathy.

MITOCHONDRIAL ALDEHYDE DEHYDROGENASE 2 DEFICIENCY AGGRAVATES ENERGY METABOLISM DISTURBANCE AND DIASTOLIC DYSFUNCTION IN DIABETIC MICE

Abstract 12954: A Genotype-Phenotype Link Between Cardiac Monoamine Oxidase Activity and Arrhythmogenic Potential Using a Translational Approach

Cardiac MAO-A inhibition protects against catecholamine-induced ventricular arrhythmias via enhanced diastolic calcium control

Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation

NAD+ Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy

Mitochondrial Aldehyde Dehydrogenase Rescues Against Diabetic Cardiomyopathy Through GSK3β-mediated Preservation of Mitochondrial Integrity and Parkin-mediated Mitophagy.

Impaired Mitochondrial Biogenesis Due to Dysfunctional Adiponectin-Ampk-pgc-1α Signaling Contributing to Increased Vulnerability in Diabetic Heart

Increased Glucose Availability Attenuates Myocardial Ketone Body Utilization

Impairment of aldehyde dehydrogenase-2 by 4-hydroxy-2-nonenal adduct formation and cardiomyocyte hypertrophy in mice fed a high-fat diet and injected with low-dose streptozotocin

Cardiac contractile function and mitochondrial respiration in diabetes-related mouse models

Mitochondrial Aldehyde Dehydrogenase Obliterates Insulin Resistance-Induced Cardiac Dysfunction Through Deacetylation of PGC-1α

Dysregulation of cardiac mitochondrial aldehyde dehydrogenase 2: Studies in dogs with chronic heart failure

Abstract 082: Deletion of Mitochondrial Aldehyde Dehydrogenase 2 Restrains Cardiac Fatty Acid Oxidation During Pressure-Overload Induced Heart Failure

Inhibition of Aldehyde Dehydrogenase 2 by Oxidative Stress Is Associated with Cardiac Dysfunction in Diabetic Rats

Mots-c Attenuates Myocardial Mitochondrial Damage Through Inhibition of Ccn1/erk1/2/egr1 Pathway

Abstract 19679: Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) Ameliorates Angiotensin II-Induced Cardiac Remodeling and Myocardial Dysfunction through Inhibition of Mitochondrial Oxidative Stress and Induction of Autophagy

Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial β-oxidation in cardiomyocytes via activation of the cardiac renin-angiotensin system and induction of miR-208a